Waltham, MA-based Proteon Therapeutics has added an additional $12 million to its first round of financing, bringing the total to $31 million. Back in March 2006, the company raised $19 million. TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners participated in the round. Proteon plans to advance its first product candidate, PRT-201, into human clinical studies in both hemodialysis vascular access and peripheral arterial disease. Proteon also added Mark J. Fitzpatrick as its Vice President and CFO.
- see this release